New drug cocktail shows promise against rare cancer
NCT ID NCT04551430
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tests whether adding two immunotherapy drugs (nivolumab and ipilimumab) to the targeted therapy cabozantinib can shrink tumors better than cabozantinib alone in people with advanced soft tissue sarcoma. About 105 participants whose cancer has spread or cannot be removed and who have tried at least one prior therapy will be enrolled. The main goal is to see how many patients have their tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center at Pennsylvania Hospital
Philadelphia, Pennsylvania, 19106, United States
-
Stanford University Medical Center
Stanford, California, 94305, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.